Browse our 650+ Publications
Latest Publications
Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-COV-2 Cytotoxic T Lymphocytes
Chu Y, et al.
April 2023
Authors and Affiliates
Yaya Chu 1 , Jordan Milner 1 , Margaret Lamb 2,3 , Elena Maryamchik 4,5 , Olivia Rigot 1 , Janet Ayello 1 , Lauren Harrison 1 , Rosemarie Shaw 1 , Gregory K Behbehani 6 , Elaine R Mardis 3,7 , Katherine Miller 7 , Lakshmi Prakruthi Rao Venkata 7 , Hsiaochi Chang 6 , Dean Lee 2,3 , Elana Rosenthal 1 , Stephan Kadauke 4 , Nancy Bunin 5,8 , Julie-An Talano 9 , Bryon Johnson 10 , Yongping Wang 4,5 , Mitchell S Cairo 1,11,12,13;
1 Department of Pediatrics, New York Medical College, Valhalla, New York, USA.
2 Department of Hematology/Oncology/Bone Marrow Transplant, Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio, USA.
3 Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA.
4 Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
5 Perlman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
6 Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, Ohio, USA.
7 The Steve and Cindy Rasmussen Institute for Genomic Medicine, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA.
8 Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
9 Department of Pediatrics, Hematology/Oncology and BMT, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
10 Department of Medicine, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
11 Department of Medicine, New York Medical College, Valhalla, New York, USA.
12 Department of Microbiology, Immunology, and Pathology, New York Medical College, Valhalla, New York, USA.
13 Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York, USA.
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer
Chow A, et al.
April 2023
Authors and Affiliates
Andrew Chow 1 , Fathema Z Uddin 2 , Michael Liu 2 , Anton Dobrin 3 , Barzin Y Nabet 4 , Levi Mangarin 5 , Yonit Lavin 2 , Hira Rizvi 6 , Sam E Tischfield 7 , Alvaro Quintanal-Villalonga 2 , Joseph M Chan 2 , Nisargbhai Shah 2 , Viola Allaj 2 , Parvathy Manoj 2 , Marissa Mattar 8 , Maximiliano Meneses 8 , Rebecca Landau 8 , Mariana Ward 8 , Amanda Kulick 8 , Charlene Kwong 8 , Matthew Wierzbicki 8 , Jessica Yavner 8 , Jacklynn Egger 6 , Shweta S Chavan 7 , Abigail Farillas 2 , Aliya Holland 5 , Harsha Sridhar 2 , Metamia Ciampricotti 2 , Daniel Hirschhorn 5 , Xiangnan Guan 4 , Allison L Richards 7 , Glenn Heller 9 , Jorge Mansilla-Soto 10 , Michel Sadelain 11 , Christopher A Klebanoff 12 , Matthew D Hellmann 13 , Triparna Sen 2 , Elisa de Stanchina 8 , Jedd D Wolchok 14 , Taha Merghoub 15 , Charles M Rudin 16;
1 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department
of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address: chowa1@mskcc.org.
2 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
3 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4 Department of Oncology Biomarker Development, Genentech, South San Francisco, CA, USA.
5 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
6 Druckenmiler Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
7 Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
8 Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
9 Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
10 Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
11 Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
12 Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer
Center, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
13 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan
Kettering Cancer Center, New York, NY, USA.
14 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program,
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
15 Ludwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Human Oncology and Pathogenesis Program,
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: tmerghoub@med.cornell.edu.
16 Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA; Druckenmiler Center for Lung Cancer Research, Memorial
Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: rudinc@mskcc.org.
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Phillips TJ, et al.
Blood Advances
April 2023
Authors and Affiliates
Tycel J. Phillips, MD1 David Bond, MD2 Radihka Takiar, MD3 Karson Kump, PhD3 Malalthi Kandarpa, PhD3 Philip Boonstra, PhD3 Tera Lynn Mayer, NP3 Victoria Nachar, Pharm D3 Ryan A. Wilcox, MD, PhD3 Shannon A. Carty, MD3
Yasmin H. Karimi, MD3 Zaneta Nikolovska-Coleska, PhD3 Mark S. Kaminski, MD3 Alex F. Herrera, MD1 Kami Maddocks, MD2 Leslie Popplewell, MD1 Alexey V. Danilov, MD1
1. City of Hope National Medical Center, Duarte, CA, 91010, 2. The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, 3. The University of Michigan Rogel Cancer Center, Ann Arbor, MI 48105
Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.
Cassaday RD, et al.
March 2023
Authors and Affiliates
Ryan D. Cassadaya,b, Lucas C. Zarlinga, Kelsey-Leigh A. Garciaa, Olga Sala-Torrab, Philip A. Stevensonc, Christen H. Martinoa,b, Yajuan J. Liud, Min Fangb,d, Mary-Elizabeth M. Percivala,b, Anna B. Halperna,b, Pamela S.Beckera,b,e, Vivian G. Oehlera,b, Andrei R. Shustova, Jason P. Coopera,b, Johnnie J. Orozcoa,b,Paul C. Hendriea,b, Roland B. Waltera,b , Jerald P. Radicha,b, Lorinda A. Somaf and Elihu H. Esteya,b
aDepartment of Medicine, University of Washington, Seattle, WA, USA; bClinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; cClinical Statistics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; dDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA; eDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA; fDepartment of Pathology, City of Hope National Medical Center, Duarte,CA, USA
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
Fonseca R, et al.
Blood Cancer Journal
March 2023
Authors and Affiliates
Rodrigo Fonseca 1, Mariano Arribas 1, Julia E. Wiedmeier-Nutor1, Yael N. Kusne1, Miguel González Vélez2, Heidi E. Kosiorek3, Richard (Duke) J. Butterfield3, Ilan R. Kirsch4, Joseph R. Mikhael 5, A. Keith Stewart6, Craig Reeder 1, Jeremy Larsen1, P. Leif Bergsagel 1 and Rafael Fonseca 1
1Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA. 2Dignity Health Cancer Institute, Phoenix, AZ, USA. 3Department of Health Sciences Research, Mayo Clinic, Scottsdale, AZ, USA. 4Translational Medicine, Adaptive Biotechnologies, Seattle, WA, USA. 5Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA. 6Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Combination IFNβ and membrane-stable CD40L maximize tumor dendritic cell activation and lymph node trafficking to elicit systemic T-cell immunity
Zheng H, et al.
February 2023
Authors and Affiliates
Hong Zheng 1, Xiaoqing Yu 2, Mohammed L Ibrahim 3, Dana Foresman 3, Mengyu Xie 4, Joseph O Johnson 2, Theresa A Boyle 2, Brian Ruffell 2, Bradford A Perez 5, Scott J Antonia 6, Neal Ready 7, Andreas N Saltos 8, Mark J Cantwell 9, Amer A Beg 10;
1 Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
2 Moffitt Cancer Center, Tampa, FL, United States.
3 Moffitt Cancer Center, Tampa, United States.
4 Moffitt Cancer Center, United States.
5 H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
6 Duke University School of Medicine, Durham, NC, United States.
7 Duke Medical Center, Durham, NC, United States.
8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States.
9 Memgen, Inc., Houston, TX, United States.
10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States.
Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium
Callaway HM, et al.
February 2023
Authors and Affiliates
Heather M. Callaway 1, Kathryn M. Hastie 1, Sharon L. Schendel 1, Haoyang Li 1, Xiaoying Yu 1, Jeremy Shek 1, Tierra Buck 1, Sean Hui 1, Dan Bedinger 2, Camille Troup 2, S. Moses Dennison 3, Kan Li 3, Michael D. Alpert 4, Charles C. Bailey 4, Sharon Benzeno 5, Jody L. Bonnevier 6, Jin-Qiu Chen 7, Charm Chen 7, Hyeseon Cho 8,9, Peter D. Crompton 8,9, Vincent Dussupt 10,11, Kevin C. Entzminger 12, Yassine Ezzyat 13, Jonathan K. Fleming 12, Nick Geukens 14, Amy E. Gilbert 5, Yongjun Guan 15,16, Xiaojian Han 17, Christopher J. Harvey 13,18, Julia M. Hatler 6, Bryan Howie 5, Chao Hu 17, Ailong Huang 19, Maya Imbrechts 14, Aishun Jin 17, Nik Kamachi 7, Gladys Keitany 5, Mark Klinger 5, Jay K. Kolls 20, Shelly J. Krebs 10,11, Tingting Li 17, Feiyan Luo 17, Toshiaki Maruyama 12, Michael A. Meehl 13, Letzibeth Mendez-Rivera 10,11, Andrea Musa 5, C.J. Okumura 12, Benjamin E.R. Rubin 5, Aaron K. Sato 21, Meiying Shen 22, Anirudh Singh 13, Shuyi Song 17, Joshua Tan 8, Jeffrey M. Trimarchi 4,23, Dhruvkumar P. Upadhyay 13,24, Yingming Wang 17, Lei Yu 25, Tom Z. Yuan 21, Erik Yusko 5, Bjoern Peters 1,26, Georgia Tomaras 3 and Erica Ollmann Saphire 1,26,27∗;
1 Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA
2 Carterra, 825 N. 300 W. Ste. C309, Salt Lake City, UT 84103, USA
3 Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA
4 Emmune, Inc., 14155 US Highway 1, Juno Beach, FL 33408, USA
5 Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102, USA
6 Bio-techne, 614 McKinley Place NE, Minneapolis, MN 55413, USA
7 ACRO Biosystems, 1 Innovation Way, Newark, DE 19711, USA
8 Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
9 Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
10 Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA
11 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA
12 Abwiz Bio, Inc., 9823 Pacific Heights Blvd. Suite J, San Diego, CA 92121, USA
13 Jounce Therapeutics, Inc., 780 Memorial Drive, Cambridge, MA 02139, USA
14 PharmAbs, The KU Leuven Antibody Center, KU Leuven, 3000 Leuven, Belgium
15 Antibody BioPharm, Inc., 401 Professional Dr Ste 241, Gaithersburg, MD 20879, USA
16 Shanghai Life Technology Co., Ltd., 781 Cai Lun Rd, Ste 801, Pudong, Shanghai 201203, China
17 Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China
18 Phenomic AI, 661 University Avenue, Suite 1300 MaRS Centre, West Tower, Toronto, ON M5G 0B7, Canada
19 Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China
20 Tulane School of Medicine, Center for Translational Research in Infection and Inflammation, New Orleans, LA 70112, USA
21 Twist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA
22 Department of Endocrine Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
23 Department of Biological Sciences, Lehigh University, 111 Research Drive, Bethlehem, PA 18015, USA
24 Amgen, Inc., 360 Binney St., Cambridge, MA 02141, USA
25 Guangzhou Eighth People’s Hospital & Guangzhou Medical University, Guangzhou 510060, China
26 Department of Medicine, University of California San Diego, La Jolla, CA 92039, USA
Erica Ollmann Saphire: gro.ijl@acire
∗Corresponding author gro.ijl@acire
27 Lead contact
Impaired SARS-CoV-2 variant neutralization and CD8+ T cell responses following 3 doses of mRNA vaccines in myeloma: correlation with breakthrough infections
Azeem MI, et al.
February 2023
Authors and Affiliates
Maryam I Azeem 1, Ajay K Nooka 2, Uma Shanmugasundaram 1, Narayanaiah Cheedarla 1, Sayalee Potdar 3, Renee Julia Manalo 3, Alberto Moreno 3, Jeffrey M Switchenko 3, Suneethamma Cheedarla 4, Deon Bryant Doxie 5, Roman Radzievski 3, Madison Leigh Ellis 3, Kelly E Manning 3, Bushra Wali 3, Rajesh M Valanparambil 2, Kathryn T Maples 3, Essence Baymon 3, Jonathan L Kaufman 6, Craig C Hofmeister 2, Nisha S Joseph 3, Sagar Lonial 7, John D Roback 3, Alessandro Sette 8, Rafi Ahmed 2, Mehul S Suthar 2, Andrew S Neish 3, Madhav V Dhodapkar 3, Kavita M Dhodapkar 9;
1 Emory University, Atlanta, Georgia, United States.
2 Emory University School of Medicine, Atlanta, GA, United States.
3 Emory University, Atlanta, GA, United States.
4 Emory University, ATLANTA, GA, United States.
5 Vanderbilt University, Atlanta, Georgia, United States.
6 Emory U. Sch. of Med., Atlanta, Ga, United States.
7 Winship Cancer Institute, Emory University, Atlanta, GA, United States.
8 La Jolla Institute for Immunology, La Jolla, CA, United States.
9 Emory University, United States.
Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma.
Urushihara R, et al.
eJHaem
January 2023
Authors and Affiliates
Ryota Urushihara1 Naoki Takezako3 Takeshi Yoroidaka1 Takeshi Yamashita4 Ryoichi Murata4 Kenji Satou2 Shinji Nakao1 Hiroyuki Takamatsu1,2
1Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan 2Faculty of Transdisciplinary Sciences for Innovation, Institute of Transdisciplinary Sciences for Innovation, Kanazawa University, Kanazawa, Japan 3Department of Hematology, Disaster Medical Center of Japan, Tachikawa, Japan 4Division of Internal Medicine, Keiju Kanazawa Hospital, Kanazawa, Japan